Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

MELBOURNE, Australia--(BUSINESS WIRE)---- $IBX #FDA--IBX announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following the FDA’s clearance of IND for a Phase 2 trial.